Whole-exome Sequencing (WES) is a targeted sequencing approach for comprehensive NGS analysis, enabling labs to focus resources on genes likely to be associated with the phenotype. WES targets protein-coding regions, which comprise less than 2% of the genome but contain ~85% of known disease variants. By producing a manageable data set, WES allows for focused analysis and competency building.
Implementation of WES in labs can provide a broad view of coding variants, enhance data management with scalable interpretation, and enable greater opportunities for re-analysis or discovery than chromosomal microarrays or gene panels alone. By using a whole-exome backbone, labs can deliver diverse and comprehensive virtual panels that simplify workflows, while being able to decrease sequencing costs and allow the execution of immediate reflex analyses.
Future-proof your tests and harness the latest genomic discoveries using flexible and dynamic virtual panels.Watch Video
A high-performance, fast, and complete whole-exome sequencing kit including library prep and hybridization reagents, a comprehensive exome probe panel, clean up/size selection beads, and indexes.
The Illumina DRAGEN Bio-IT Platform provides accurate, comprehensive, and efficient analysis of next-generation sequencing data.
This sequencer introduces over 75 breakthrough innovations to deliver a faster, more intuitive experience in next-generation sequencing.
While targeted sequencing can identify important genomic insights, whole-genome sequencing (WGS) is the most comprehensive assay for rare disease genomics.
On Rare Disease Day 2023, Illumina spotlights four patient organizations and accelerates iHopeRead Article
Whole-exome and transcriptome sequencing prove beneficial in uncovering mutations and pathways associated with rare disease.Read Interview
Igentify’s digital genetic engine can help people screen for hundreds of autosomal recessive disordersRead Article
Dr. Kenjiro Kosaki furthers his clinical research and expands the genetic analysis services he provides with the TruSight One Sequencing Panel. Learn why he thinks genomic technology will drastically change how we assess patients suffering from undiagnosed disorders.Read Interview
The TruSight Cystic Fibrosis 139-Variant Assay is an FDA-cleared, CE-IVD-marked NGS test designed to detect 139 CFTR variants as defined in the CFTR2 database. Other methods test only for those variants most commonly found in Caucasians, potentially missing CF-causing variants across broader ethnic groups. The assay offers the largest CF variant panel to overcome this bias and provide comprehensive detection across diverse demographics.1
The TruSight One Sequencing Panel provides comprehensive coverage of > 4800 disease-associated genes, while the TruSight One Expanded Sequencing Panel targets ~1900 additional genes with recent disease associations in the scientific literature.
Personalized medicine programs can help match patients to treatments, reduce disease burden, increase survival rates, and reduce the cost of care.Learn More